Background
Prospective randomized phase II trial (n=324) of stage II or III locally advanced rectal adenocarcinoma comparing two total neoadjuvant therapy (TNT) sequences, with non-operative watch-and-wait management for clinical complete responders and comparison to historical controls.
Interventions and follow up
Arm A (induction): induction chemotherapy (FOLFOX or CAPEOX) then chemoradiotherapy
Arm B (consolidation): chemoradiotherapy then consolidation chemotherapy; restaging by exam, MRI, or CT within 8 weeks of TNT
Management: clinical complete or near-complete responders offered watch-and-wait; incomplete responders recommended TME
Primary endpoint: disease-free survival
Median follow up: 3 years
Arm B (consolidation): chemoradiotherapy then consolidation chemotherapy; restaging by exam, MRI, or CT within 8 weeks of TNT
Management: clinical complete or near-complete responders offered watch-and-wait; incomplete responders recommended TME
Primary endpoint: disease-free survival
Median follow up: 3 years
Results
3-yr DFS: 76% vs 76%, arm A vs B (similar)
Historical control 3-yr DFS: 75%
3-yr TME-free survival: 41% vs 53%, arm A vs B (favoring consolidation)
Salvage TME: patients undergoing TME after restaging vs after regrowth had similar DFS
Historical control 3-yr DFS: 75%
3-yr TME-free survival: 41% vs 53%, arm A vs B (favoring consolidation)
Salvage TME: patients undergoing TME after restaging vs after regrowth had similar DFS
Adverse events
Overall grade ≥3: ~38% of patients; TNT regimens generally tolerable
Hematologic/GI: neutropenia and diarrhea most common; no new safety signals beyond known FOLFOX/CAPEOX and pelvic chemoradiation toxicities
Hematologic/GI: neutropenia and diarrhea most common; no new safety signals beyond known FOLFOX/CAPEOX and pelvic chemoradiation toxicities
Conclusions
Total neoadjuvant therapy achieved disease-free survival comparable to historical chemoradiotherapy-surgery-adjuvant controls while allowing roughly half of patients to avoid total mesorectal excision via organ preservation; consolidation chemotherapy yielded higher TME-free survival.
Key Limitations
DFS comparison relied on historical rather than randomized controls. Phase II size limits power for survival; durability of organ preservation and long-term local regrowth rates require extended follow-up. FOLFOX (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, FU 400 mg/m2 bolus + 2400 mg/m2 over 46–48h, Q14D ×8) or CAPEOX (oxaliplatin 130 mg/m2 D1 + capecitabine 1000 mg/m2 BID D1–14, Q21 ×5); CRT = capecitabine 825 mg/m2 BID or infusional 5-FU 225 mg/m2/day with 5000–5600 cGy.
Clinical Context
A key trial supporting total neoadjuvant therapy with selective non-operative (watch-and-wait) management for LARC; consolidation chemotherapy sequencing increased organ-preservation rates, informing ASCO/ESMO-aligned TNT and organ-preservation strategies.